GreenApple78
BridgeBio Pharma (NASDAQ:BBIO) said positive results from its Phase 3 ATTRibute-CM study for its drug acoramidis in the treatment of transthyretin amyloid cardiomyopathy, or ATTR-CM, have been published in the New England Journal of Medicine.
The biotech company released topline results from the study in July and presented additional data at the European Society of Cardiology Congress in August and the American Heart Association Scientific Sessions in November, according to a statement.
BridgeBio submitted a market application to the FDA for acoramidis in December. It intends to submit applications for market approval from additional regulatory bodies this year.
If approved, acoramidis would compete against Pfizer’s (PFE) Vyndamax/Vyndaquel, also known as tafamidis, which is also approved to treat the condition.
